STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCAX
  4. [8-K] Bicara Therapeutics Inc. Reports Material Event

Cash runway into 2029 as Bicara (Nasdaq: BCAX) posts larger Q1 2026 loss

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Bicara Therapeutics reported first quarter 2026 results and highlighted progress advancing its lead cancer asset ficerafusp alfa. Cash, cash equivalents and marketable securities were $539.8 million as of March 31, 2026, up from $414.8 million at December 31, 2025, helped by approximately $161.8 million in net proceeds from an oversubscribed public offering. The company expects this cash to fund operations into the first half of 2029.

Research and development expenses rose to $47.5 million from $34.3 million a year earlier, and general and administrative expenses increased to $12.7 million from $7.5 million, reflecting pivotal FORTIFI-HN01 trial costs, Phase 1/1b expansions and higher personnel and professional fees. Net loss widened to $56.2 million, or $0.93 per share, compared with $36.8 million, or $0.68 per share, in the prior-year quarter.

Operationally, Bicara continued enrollment in its pivotal FORTIFI-HN01 trial in first-line HPV-negative head and neck cancer and plans a randomized alternate-dose study of ficerafusp alfa with pembrolizumab starting in the third quarter of 2026. The company expects to present long-term Phase 1b data at ASCO 2026 and additional data in other solid tumors later in 2026. Leadership changes included promoting Bill Schelman to Chief Medical Officer and appointing Chris Sarchi as Chief Commercial Officer to support potential commercialization.

Positive

  • None.

Negative

  • None.

Insights

Bicara strengthens cash runway while losses widen as trials scale.

Bicara ended March 31, 2026 with $539.8 million in cash, cash equivalents and marketable securities, supported by $161.8 million in net proceeds from an oversubscribed Q1 offering. Management believes this will fund operations into the first half of 2029, giving substantial runway for late-stage development.

Spending increased as the company advanced its FORTIFI-HN01 pivotal trial and multiple Phase 1/1b cohorts. Research and development expenses rose to $47.5 million from $34.3 million, while general and administrative expenses climbed to $12.7 million from $7.5 million, contributing to a net loss of $56.2 million.

Execution now centers on clinical milestones: substantial enrollment of FORTIFI-HN01 by year-end to enable an interim analysis in mid-2027, initiation of an alternate-dose study in Q3 2026, and key data updates at ASCO 2026 and in the second half of 2026. These events will help clarify ficerafusp alfa’s profile in head and neck cancer and other solid tumors.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Cash, cash equivalents and marketable securities $539.8 million As of March 31, 2026
Cash, cash equivalents and marketable securities $414.8 million As of December 31, 2025
Net proceeds from public offering $161.8 million Oversubscribed offering in Q1 2026
Research and development expenses $47.5 million Three months ended March 31, 2026
General and administrative expenses $12.7 million Three months ended March 31, 2026
Net loss $56.2 million Three months ended March 31, 2026
Net loss per share $0.93 Basic and diluted, Q1 2026
Weighted-average shares outstanding 60,717,041 shares Basic and diluted, Q1 2026
FORTIFI-HN01 medical
"Continued strong execution in FORTIFI-HN01, our pivotal trial in 1L HPV-negative R/M HNSCC"
accelerated approval regulatory
"interim analysis in mid-2027 to support potential accelerated approval"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
bifunctional therapies medical
"Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients"
transforming growth factor beta (TGF-β) medical
"a human transforming growth factor beta (TGF-β) ligand trap"
marketable securities financial
"cash, cash equivalents and marketable securities of $539.8 million"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
American Society of Clinical Oncology (ASCO) medical
"at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting"
A major professional organization for cancer doctors and researchers that organizes influential conferences, publishes clinical guidance and peer-reviewed research, and sets standards for cancer care. For investors, ASCO’s meetings and publications often reveal early clinical trial results, treatment trends and guideline changes that can affect the commercial prospects of drugs, diagnostic tools and medical services—think of it as both a trade show and a rule book for the oncology field.
Net loss $56.2 million
R&D expenses $47.5 million
G&A expenses $12.7 million
Cash, cash equivalents and marketable securities $539.8 million
Understanding 8-K Material Events →
FALSE000202365800020236582026-05-112026-05-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 11, 2026

___________________________________
Bicara Therapeutics Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
(State or other jurisdiction of
incorporation or organization)
001-42271
(Commission File Number)
83-2903745
(I.R.S. Employer Identification Number)
116 Huntington Avenue, Suite 703
Boston, MA 02116
(Address of principal executive offices and zip code)
(617) 468-4219
(Registrant's telephone number, including area code)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
BCAX
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company    ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 2.02 - Results of Operations and Financial Condition.
On May 11, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 - Financial Statements and Exhibits
(d) The following exhibits are being filed herewith:

Exhibit No.
Description
99.1
Press Release of Bicara Therapeutics Inc., dated May 11, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 11th day of May, 2026.



Bicara Therapeutics Inc.
By:
/s/ Claire Mazumdar
Name:
Claire Mazumdar
Title:
Chief Executive Officer


bicaralogoa.jpg

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026

Long-term follow-up data from Phase 1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC patients to be presented at ASCO 2026

Bill Schelman, M.D., Ph.D., EVP, Clinical Development promoted to Chief Medical Officer, and David Raben, M.D., Chief Medical Officer transitioned to serve as a Senior Executive Advisor to the company

Chris Sarchi appointed as Chief Commercial Officer


BOSTON, May 11, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX) today announced financial results for the first quarter ended March 31, 2026 and provided a business update.

“The first quarter of 2026 reflects strong progress as we work to position ficerafusp alfa as the cornerstone of treatment in HPV-negative head and neck cancer. In addition to advancing our FORTIFI-HN01 pivotal trial, we continued to enroll patients in additional Phase 1b signal-seeking studies as we aim to unlock the full blockbuster potential of ficerafusp alfa. Based on recent FDA discussions, we plan to initiate a randomized study to evaluate a loading and every-three-week maintenance dosing regimen – further differentiating ficerafusp alfa and expanding optionality for patients and providers. We also look forward to sharing an important data update at ASCO 2026, which will further characterize the role of TGF-β in driving depth and durability of response across three 1L R/M HNSCC expansion cohorts,” said Claire Mazumdar, Ph.D., Chief Executive Officer at Bicara Therapeutics. “Alongside our clinical progress, we are rapidly evolving toward becoming a commercial-stage company, and to support that evolution, today we announced several executive changes. David Raben has transitioned from Chief Medical Officer to a Senior Executive Advisor role after three years of instrumental contributions, and Bill Schelman, formerly Executive Vice President of Clinical Development, has stepped into the Chief Medical Officer role. We have also welcomed Chris Sarchi as our Chief Commercial Officer, who brings extensive oncology commercialization and leadership experience as we build toward launch.”

First Quarter 2026 Highlights and Recent Progress

FORTIFI-HN01: Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in First Line (1L) Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

•Continued strong execution in FORTIFI-HN01, our pivotal trial in 1L HPV-negative R/M HNSCC; expect to be substantially enrolled by the end of the year to enable an interim analysis in mid-2027 to support potential accelerated approval.

•Based on recent discussions with the U.S. Food and Drug Administration (FDA), the company plans to initiate a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by


maintenance dosing of 2250mg every three weeks (Q3W). The company expects to initiate the study in the third quarter of 2026 to have results in time for potential U.S. accelerated approval.

Phase 1b Studies of Ficerafusp Alfa Across HNSCC and Other Solid Tumor Types

•Continued to enroll multiple Phase 1b expansion cohorts to identify early proof-of-concept signals and inform ficerafusp alfa development strategy beyond 1L R/M HPV-negative HNSCC.
•Published a manuscript detailing results from a Phase 1b expansion cohort evaluating 1500mg of ficerafusp alfa QW in combination with pembrolizumab in 1L R/M HNSCC in the Journal of Clinical Oncology. Read the manuscript here.

Corporate Highlights

•Announced that effective May 8, 2026, Bill Schelman, M.D., Ph.D., previously the company’s Executive Vice President, Clinical Development, has succeeded David Raben, M.D., as Chief Medical Officer, and Dr. Raben has transitioned to serve as a Senior Executive Advisor. With this promotion, Dr. Schelman is responsible for medical affairs and clinical development. In his new role, Dr. Raben will advise on clinical development strategy across the company’s portfolio.

•Announced that effective May 8, 2026, Chris Sarchi was appointed as Chief Commercial Officer. In this role, he will lead the commercial organization in preparation for launch readiness.


Key Anticipated Upcoming Milestones

HNSCC

•Present long-term follow-up data, which will further characterizing the role of TGF-β inhibition in driving depth and durability of response, from three Phase 1b expansion cohorts of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29-June 2, 2026 in Chicago, IL.

Other Solid Tumors, Including mCRC

•Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in the second half of 2026.

First Quarter 2026 Financial Results

•Cash, Cash Equivalents and Marketable Securities: As of March 31, 2026, Bicara had cash, cash equivalents and marketable securities of $539.8 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025. The company received approximately $161.8 million in net proceeds from an oversubscribed public offering in the first quarter of 2026. Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029.

•Research and Development Expenses: Research and development expenses were $47.5 million for the first quarter of 2026 as compared to $34.3 million for the first quarter of 2025. The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, as well as the company’s ongoing Phase 1/1b dose expansion cohorts, and an increase in personnel costs.



•General and Administrative Expenses: General and administrative expenses were $12.7 million for the first quarter of 2026 as compared to $7.5 million for the first quarter of 2025. The increase was primarily due to additional personnel costs and professional fees to support advancement of our clinical trials.

•Net Loss: Net loss totaled $56.2 million for the first quarter of 2026 compared to $36.8 million for the first quarter of 2025.

Upcoming Investor Conferences

Bicara Therapeutics will participate in two upcoming investor conferences:

•BofA Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 9:20 a.m. PT.
•TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 10:30 a.m. ET.

A live webcast of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available for 30 days following the event.

Conference Call Information

Bicara will host a live conference call and webcast at 8:30 a.m. ET today to discuss first quarter 2026 financial results and recent business activities. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.

About Bicara Therapeutics

Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not


all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding Bicara’s strategy, business plans and focus; the clinical development of ficerafusp alfa, including the initiation, timing, progress, results and future data releases of Bicara’s ongoing and planned clinical trials; the advancement of the FORTIFI-HN01 pivotal trial in 1L HPV-negative R/M HNSCC and Bicara’s expectation for the trial to be substantially enrolled by the end of the year and an interim analysis mid-2027; the timing of future data releases from Bicara’s ongoing Phase 1/1b expansion cohorts; the initiation of an alternate dose study in the third quarter of 2026 to evaluate a loading and every-three-week maintenance dosing regimen of ficerafusp alfa and expectations for results in time for potential U.S. accelerated approval; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability and tolerability as compared to the existing standard of care; Bicara’s ability to scale and prepare for potential commercialization of ficerafusp alfa; anticipated contributions of members of Bicara’s leadership team; the potential for regulatory approval and U.S. launch of ficerafusp alfa; and Bicara’s expected operating expenses and capital expenditure requirements, including its cash runway into the first half of 2029. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks relating to Bicara’s research and development activities; Bicara’s ability to execute on its business plans and strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to the clinical development of ficerafusp alfa; the Company’s dependence on third parties; risks related to the Company’s financial condition and need for additional funds in order to commercialize ficerafusp alfa, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Bicara’s intellectual property protections; and risks related to the competitive landscape for ficerafusp alfa; as well as other risks described in “Risk Factors,” in Bicara’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Bicara’s subsequent filings with the U.S. Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.


BICARA THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, in thousands except shares and per share data)

Three Months Ended March 31,
20262025
Operating expenses
Research and development$47,500 $34,333 
General and administrative12,742 7,455 
Total operating expenses1
60,242 41,788 
Loss from operations(60,242)(41,788)
Other income
Interest income4,083 5,014 
Total other income4,083 5,014 
Net loss before income taxes(56,159)(36,774)
Income tax expense(52)(72)
Net loss$(56,211)$(36,846)
Net Loss per share, basic and diluted$(0.93)$(0.68)
Weighted-average number common shares outstanding, basic and diluted60,717,04154,456,515
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax(486)— 
Total other comprehensive loss(486)— 
Total comprehensive loss$(56,697)$(36,846)
1 Expenses include the following non-cash stock-based compensation expense
Research & Development$2,225 $1,141 
General and administrative3,633 2,310 
Total stock-based compensation expense.$5,858 $3,451 









BICARA THERAPEUTICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)


March 31, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$323,462$96,685
Prepaid expenses and other assets5,1627,252
Marketable securities216,291318,116
Total current assets544,915422,053
Property and equipment, net346330
Right of use asset – operating lease1,4281,701
Other assets6,9106,910
Total assets$553,599$430,994
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$6,188$5,515
Accounts payable – related party1,2522,278
Accrued expenses and other current liabilities29,94818,898
Accrued expenses and other current liabilities – related party8121,141
Operating lease liability – current portion1,1401,117
Total current liabilities39,34028,949
Operating lease liability – net of current portion301593
Total liabilities39,64129,542
Total stockholders' equity513,958401,452
Total liabilities and stockholders’ equity$553,599$430,994












Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Tim Palmer
tim.palmer@bicara.com

Source: View Original Filing on SEC EDGAR

FAQ

How did Bicara Therapeutics (BCAX) perform financially in Q1 2026?

Bicara reported a Q1 2026 net loss of $56.2 million, or $0.93 per share, compared with a $36.8 million loss, or $0.68 per share, in Q1 2025, reflecting higher research, development, and administrative spending as clinical programs advanced.

What is Bicara Therapeutics’ cash position and runway after Q1 2026?

As of March 31, 2026, Bicara held $539.8 million in cash, cash equivalents and marketable securities, up from $414.8 million at year-end 2025. It received about $161.8 million in net proceeds from an oversubscribed public offering and expects current funds to last into the first half of 2029.

How did Bicara’s R&D and G&A expenses change in Q1 2026?

Research and development expenses rose to $47.5 million in Q1 2026 from $34.3 million a year earlier, mainly from the FORTIFI-HN01 pivotal trial and Phase 1/1b cohorts. General and administrative expenses increased to $12.7 million from $7.5 million, driven by added personnel and professional fees.

What are the key clinical milestones for Bicara Therapeutics after Q1 2026?

Bicara expects its FORTIFI-HN01 pivotal trial in first-line HPV-negative head and neck cancer to be substantially enrolled by year-end, enabling an interim analysis in mid-2027. It also plans to start a randomized alternate-dose study in Q3 2026 and present new data at ASCO 2026.

What leadership changes did Bicara Therapeutics announce with its Q1 2026 update?

Effective May 8, 2026, Bill Schelman, M.D., Ph.D. became Chief Medical Officer, succeeding David Raben, M.D., who moved to Senior Executive Advisor. Chris Sarchi was appointed Chief Commercial Officer to lead commercialization efforts as the company prepares for potential future product launch.

What is ficerafusp alfa and how is Bicara developing it?

Ficerafusp alfa is Bicara’s lead bifunctional therapy, combining an EGFR-directed antibody with a TGF-β ligand trap to target tumors and modulate the microenvironment. It is being developed in head and neck squamous cell carcinoma and other solid tumors, including pivotal and Phase 1b studies.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents